Literature DB >> 30879932

Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.

Yanwu Sun1, Xuejing Wu2, Yiyi Zhang1, Huiming Lin1, Xingrong Lu1, Ying Huang1, Pan Chi3.   

Abstract

AIM: To evaluate the pattern of tumor relapse of pathological complete response (pCR) patients with locally advanced rectal cancer (LARC) following neoadjuvant chemoradiotherapy (nCRT) and total mesorectal excision (TME), and to identify predictive factors of distant metastasis in pCR patients after nCRT.
METHOD: This was a retrospective analysis of 118 LARC patients who achieved a pCR following nCRT and TME from 2008 to 2015. Clinicopathological and therapeutic parameters were evaluated as possible predictors of distant metastasis-free survival (DMFS), and COX regression analysis was performed.
RESULTS: After a median follow-up of 57 months, the 5-year overall and disease-free survival rates were 94.7% and 88.1%, respectively. Overall, 6 patients (5.1%) died, no local recurrence occurred, 13 patients (11%) developed distant metastases, including lung (n = 5), liver (n = 2), bone (n = 3), lung and brain (n = 1), peritoneal (n = 1), and spleen (n = 1) metastasis. On univariate analysis, tumor distance from the anal verge (HR = 0.706, P = 0.039), acellular mucin pools (HR = 6.687, P = 0.002), and MUC1 expression (HR = 8.280, P < 0.001) were independently associated with DMFS. COX regression demonstrated that MUC1 expression (HR = 3.812, P = 0.041) remained to be an independent predictor of DMFS in pCR patients.
CONCLUSION: Distant metastasis still remained a major concern in pCR patients following nCRT and TME. Tumor distance from the anal verge, acellular mucin pools, and MUC1 expression were associated with distant metastasis in patients with pCR. MUC1 staining remained to be an independent risk factor for DMFS. Such information could facilitate treatment decision in these patients, such as adjuvant chemotherapy and follow-up.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Metastasis; Pathological complete response; Prognosis; Rectal cancer

Mesh:

Substances:

Year:  2019        PMID: 30879932     DOI: 10.1016/j.ejso.2019.03.005

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

1.  Pre-Treatment Computed Tomography Radiomics for Predicting the Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Retrospective Study.

Authors:  Yitao Mao; Qian Pei; Yan Fu; Haipeng Liu; Changyong Chen; Haiping Li; Guanghui Gong; Hongling Yin; Peipei Pang; Huashan Lin; Biaoxiang Xu; Hongyan Zai; Xiaoping Yi; Bihong T Chen
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

2.  MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.

Authors:  Xiaoxuan Jia; Peiyi Xie; Liang Bi; Xiaochun Meng; Ziqiang Wang; Nan Hong; Yi Wang
Journal:  Br J Radiol       Date:  2021-02-16       Impact factor: 3.039

3.  Qingjie Fuzheng Granules regulates cancer cell proliferation, apoptosis and tumor angiogenesis in colorectal cancer xenograft mice via Sonic Hedgehog pathway.

Authors:  Xiao-Qin Zhu; Hong Yang; Ming-He Lin; Hai-Xia Shang; Jun Peng; Wu-Jin Chen; Xu-Zheng Chen; Jiu-Mao Lin
Journal:  J Gastrointest Oncol       Date:  2020-12

Review 4.  Prognostic and Clinicopathological Significance of MUC Family Members in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Chao Li; Didi Zuo; Tao Liu; Libin Yin; Chenyao Li; Lei Wang
Journal:  Gastroenterol Res Pract       Date:  2019-12-20       Impact factor: 2.260

5.  Anlotinib suppresses metastasis and multidrug resistance via dual blockade of MET/ABCB1 in colorectal carcinoma cells.

Authors:  Lin-Hai Yan; Di Zhang; Si-Si Mo; Hao Yuan; Xian-Wei Mo; Jin-Min Zhao
Journal:  J Cancer       Date:  2021-02-16       Impact factor: 4.207

6.  Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety.

Authors:  Jintian Song; Yi Wang; Hui Yu; Liang Zheng; Xiongchao Cai; Yigui Chen
Journal:  Comput Math Methods Med       Date:  2021-12-09       Impact factor: 2.238

7.  Combination of Changes in CEA and CA199 Concentration After Neoadjuvant Chemoradiotherapy Could Predict the Prognosis of Stage II/III Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Followed by Total Mesorectal Excision.

Authors:  Jieyi Zhao; Huamin Zhao; Tingting Jia; Shiru Yang; Xiaoyu Wang
Journal:  Cancer Manag Res       Date:  2022-09-29       Impact factor: 3.602

8.  Nomogram to Predict Distant Metastasis Probability for Pathological Complete Response Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy.

Authors:  Ting Jiang; Shuang Liu; Xiaojun Wu; Xiaoqing Liu; Weizhan Li; Shanfei Yang; Peiqiang Cai; Shaoyan Xi; Zhifan Zeng; Yuanhong Gao; Gong Chen; Weiwei Xiao
Journal:  Cancer Manag Res       Date:  2021-06-15       Impact factor: 3.602

9.  Prognostic impact of acellular mucin pools towards the patients with locally advanced rectal cancer achieving pathological complete response after preoperative chemoradiotherapy.

Authors:  Lin Zhang; Huajie Guan; Qiuyun Luo; Lifang Yuan; Yulan Mao; Xiaojun Wu; Zhizhong Pan; Junzhong Lin; Jianhong Peng
Journal:  Therap Adv Gastroenterol       Date:  2020-03-25       Impact factor: 4.409

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.